Shionogi & Co Ltd (4507.T)
17 Nov 2017
* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31
* Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States
* Shionogi & Co Ltd - Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study
TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.
TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.
* SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD Source text for Eikon: Further company coverage: (Bangalore.firstname.lastname@example.org)
* Shionogi - announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients
* Says it lowers the conversion price for 2019 due euro-yen denominated convertible bonds to 4,150.9 yen per share, from 4,167.5 yen per share, effective April 1
BRIEF- PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi
* Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology